Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study
Open Access
- 1 October 2005
- journal article
- clinical trial
- Published by American Society of Hematology in Blood
- Vol. 106 (7) , 2269-2275
- https://doi.org/10.1182/blood-2004-12-4973
Abstract
The long-term efficacy and toxicity of hydroxyurea for infants are undefined, and its role in preventing organ dysfunction is unknown. Short-term feaKeywords
This publication has 52 references indexed in Scilit:
- A case for developing North-South partnerships for research in sickle cell diseaseBlood, 2005
- Invasive pneumococcal infections in children with sickle cell disease in the era of penicillin prophylaxis, antibiotic resistance, and 23-valent pneumococcal polysaccharide vaccinationThe Journal of Pediatrics, 2003
- Hydroxyurea-induced splenic regrowth in an adult patient with severe hemoglobin SC diseaseAmerican Journal of Hematology, 2003
- A two-year pilot trial of hydroxyurea in very young children with sickle-cell anemiaThe Journal of Pediatrics, 2001
- Clinical and hematologic effects of hydroxyurea in children with sickle cell anemiaThe Journal of Pediatrics, 1996
- Effect of Hydroxyurea on the Frequency of Painful Crises in Sickle Cell AnemiaNew England Journal of Medicine, 1995
- Sickle Cell Chronic Lung DiseaseMedicine, 1988
- Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia.Journal of Clinical Investigation, 1984
- Influence of Sickle Hemoglobinopathies on Growth and DevelopmentNew England Journal of Medicine, 1984
- Post-natal decline of fetal haemoglobin in homozygous sickle cell disease: relationship to parental Hb F levelsBritish Journal of Haematology, 1982